Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      FDA warns more doctors of rare cancer with breast implants

      FDA warns more doctors of rare cancer with breast implants

      Farhat Nasim10 Feb 2019 9:15 AM IST
      The FDA has been tracking reports of cancer for years and officially confirmed its link to breast implants in 2017.WASHINGTON: U.S. health officials...
      Zydus Cadila gets USFDA nod for Carbamazepine extended release tablets

      Zydus Cadila gets USFDA nod for Carbamazepine extended release tablets

      Farhat Nasim9 Feb 2019 10:00 AM IST
      Carbamazepine is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve...
      Lupin gets 2 observations from USFDA for its Goa facility

      Lupin gets 2 observations from USFDA for its Goa facility

      Farhat Nasim9 Feb 2019 9:45 AM IST
      Mumbai: Soon after the inspection of its facility in Madhya Pradesh, the Mumbai-based, Lupin Ltd recently got a couple of key observations for it's...
      Pharmacy stocks run low; Diabetes, BP patients leave empty handed

      Pharmacy stocks run low; Diabetes, BP patients leave empty handed

      Farhat Nasim9 Feb 2019 9:00 AM IST
      * Pharmacists say medicine warehouses don't have drugs * Government forex curbs affect prices firms can charge* Health ministry says will raise prices...
      Narayana Hrudayalaya former MD, CEO Ashutosh Raghuvanshi joins Fortis Healthcare as new CEO

      Narayana Hrudayalaya former MD, CEO Ashutosh Raghuvanshi joins Fortis Healthcare as new CEO

      Farhat Nasim8 Feb 2019 11:59 AM IST
      New Delhi: Ex-Managing Director(MD) and Group CEO of Narayana Hrudayalaya, Ashutosh Raghuvanshi has been appointed as the new Chief Executive...
      Glenmark gets tentative USFDA nod to breast cancer injection Fulvestrant

      Glenmark gets tentative USFDA nod to breast cancer injection Fulvestrant

      Farhat Nasim8 Feb 2019 11:40 AM IST
      Fulvestrant injection is a generic version of AstraZeneca Pharmaceuticals LP's Faslodex injection in the same strength, it added. The Faslodex...
      Lupin posts Q3 loss of Rs 152 crore on litigation over Perindopril

      Lupin posts Q3 loss of Rs 152 crore on litigation over Perindopril

      Farhat Nasim7 Feb 2019 2:23 PM IST
      Lupin had a net loss of 1.52 billion rupees compared to a profit of 2.22 billion rupees in the same quarter last year, the company said.Mumbai: A...
      Strides Pharma gets EIR for Bangalore facility

      Strides Pharma gets EIR for Bangalore facility

      Farhat Nasim7 Feb 2019 11:32 AM IST
      "The company's formulations facility (KRSG Gardens) in Bangalore which was inspected by the US Food and Drug Administration (USFDA) in August 2018 and...
      Sanofi gets FDA nod to blood disorder drug Cablivi

      Sanofi gets FDA nod to blood disorder drug Cablivi

      Farhat Nasim7 Feb 2019 9:30 AM IST
      Cablivi was originally developed by Ablynx, a Belgium biotech firm that Sanofi acquired in January last year for 3.9 billion euros ($4.53 billion)...
      EMA committee recommends Roche Tecentriq in combo with Avastin and chemotherapy

      EMA committee recommends Roche Tecentriq in combo with Avastin and chemotherapy

      Farhat Nasim7 Feb 2019 9:00 AM IST
      CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer.Zurich: Roche...
      Akum Drugs, Lupin, DRL bags India Pharma Award 2019; Details

      Akum Drugs, Lupin, DRL bags India Pharma Award 2019; Details

      Farhat Nasim6 Feb 2019 9:40 AM IST
      The awards will be conferred during the India Pharma 2019 and India Medical Device 2019 to be held on 18th February 2019.New Delhi: Various...
      Biocon Foundation Cancer Task Force recommends guidelines for Cancer Care

      Biocon Foundation Cancer Task Force recommends guidelines for Cancer Care

      Farhat Nasim6 Feb 2019 9:30 AM IST
      Biocon Foundation, Kiran Mazumdar-Shaw said, “Given that a third of oral cancer cases in the world are reported in India, it is a huge opportunity...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok